Savolitinib: all 41 studies that test it
Page 1 of 1. Open to participants first (4), then studies with results posted, then the rest; newest registration first within each.
- Study of Precision Treatment for Rare Tumours in China Guided by PDO and NGSNot yet recruitingNCT06692491Phase 2
- Neoadjuvant Umbrella Trial for Patients With Unresectable Stage III NSCLC Harboring Rare Mutations.RecruitingNCT06563999Phase 2
- Savolitinib Plus Docetaxel as 2L in EGFR/ALK/ROS1/MET ex14m-wildtype NSCLC With MET OverexpressionRecruitingNCT05777278Phase 1/2
- Ph2 Study of Savolitinib and Durvalumab (MEDI4736) Combination in Advanced MET Amplified Gastric Cancer(VIKTORY-2)RecruitingNCT05620628Phase 2
- A Study Comparing Savolitinib Plus Osimertinib vs Savolitinib Plus Placebo in Patients With EGFRm+ and MET Amplified Advanced NSCLCActive, not recruitingNCT04606771Phase 2Results posted
- Savolitinib in Treating Patients With Recurrent or Refractory Primary CNS TumorsActive, not recruitingNCT03598244Phase 1Results posted
- Savolitinib in Treating Patients With MET Amplified Metastatic or Unresectable Colorectal CancerTerminatedNCT03592641Phase 2Results posted
- Savolitinib vs. Sunitinib in MET-driven PRCC.Active, not recruitingNCT03091192Phase 3Results posted
- Testing Cabozantinib, Crizotinib, Savolitinib and Sunitinib in Kidney Cancer Which Has ProgressedCompletedNCT02761057Phase 2Results posted
- A Phase II Trial to Evaluate the Efficacy of AZD6094 (HMPL-504) in Patients With Papillary Renal Cell Carcinoma (PRCC)CompletedNCT02127710Phase 2Results posted
- A Positron-emission Tomography Study to Determine Brain Exposure of [11C]Savolitinib in Healthy VolunteersCompletedNCT06348355Phase 1
- A Study to Assess the Effects of Fluvoxamine on Savolitinib Exposure in Healthy Male SubjectsCompletedNCT05888207Phase 1
- A Study to Assess the Effects of Savolitinib on the Pharmacokinetics of Digoxin, Rosuvastatin, Metformin, and Furosemide in Healthy Male SubjectsCompletedNCT05768360Phase 1
- Savolitinib Combine With Durvalumab in EGFR Wild-type Locally Advanced or Metastatic NSCLCActive, not recruitingNCT05374603Phase 2
- Savolitinib Plus Osimertinib Versus Platinum-based Doublet Chemotherapy in Participants With Non-Small Cell Lung Cancer Who Have Progressed on Osimertinib TreatmentActive, not recruitingNCT05261399Phase 3
- Osimertinib With or Without Savolitinib as 1L in de Novo MET+, EGFR+ NSCLCActive, not recruitingNCT05163249Phase 2
- Savolitinib Plus Durvalumab Versus Sunitinib and Durvalumab Monotherapy in MET-Driven, Unresectable and Locally Advanced or Metastatic PRCCActive, not recruitingNCT05043090Phase 3
- Study on Savolitinib Combined With Osimertinib in Treatment of Advanced NSCLC With MET AmplificationCompletedNCT05015608Phase 3
- Clinical Study on Savolitinib + Osimertinib in Treatment of EGFRm+/MET+ Locally Advanced or Metastatic NSCLCActive, not recruitingNCT05009836Phase 3
- Savolitinib for Treating Locally Advanced or Metastatic Non-small Cell Lung Cancer (NSCLC) PatientsCompletedNCT04923945Phase 3
- Savolitinib for Treating Gastric Cancer and Esophagogastric Junction Adenocarcinoma PatientsCompletedNCT04923932Phase 2
- Absolute Bioavailability and ADME Study of Savolitinib in Healthy Male SubjectsCompletedNCT04675021Phase 1
- A Study in Healthy Male Subjects to Understand How Savolitinib When Taken With Midazolam Behaves Inside the BodyCompletedNCT04187456Phase 1
- A Study in Healthy Male Subjects to Understand How Savolitinib Behaves Inside the Body (Pharmacokinetics) When Administered Alone and in Combination With FamotidineCompletedNCT04179071Phase 1
- A Study to Evaluate the Amount of Drug That Becomes Available in the Blood Circulation When Savolitinib is Administered Alone and in Combination With ItraconazoleCompletedNCT04121910Phase 1
- A Study in Healthy Subjects to Assess the Pharmacokinetics of Savolitinib When Administered Alone and in Combination With RifampicinCompletedNCT04118842Phase 1
- Precision Immuno-Oncology for Advanced Non-small Cell Lung Cancer Patients With PD-1 ICI ResistanceActive, not recruitingNCT03833440Phase 2
- Prostate Cancer Biomarker Enrichment and Treatment SelectionActive, not recruitingNCT03385655Phase 2
- A Study to Investigate the Effect of Single Dose of AZD6094 (600 mg) on Cardiac Repolarization in Healthy VolunteersCompletedNCT03258515Phase 1
- A Phase II Study of HMPL-504 in Lung Sarcomatoid Carcinoma and Other Non-small Cell Lung CancerStatus unknownNCT02897479Phase 2
- MEDI4736 Combinations in Metastatic Renal Cell CarcinomaCompletedNCT02819596Phase 2
- Cetuximab and Savolitinib Treatment of Ras Wild-Type Colorectal CancerWithdrawnNCT02630420Phase 1
- Study of AZD6094 (Volitinib) in Advanced Gastric Adenocarcinoma Patients With MET Amplification as a Third-line TreatmentCompletedNCT02449551Phase 2
- Phase Ib, Single-arm Study of AZD6094 (Volitinib) in Combination With Docetaxel, in Any Solid Cancer and Sequential Phase II, Single-arm Study of AZD6094 (Volitinib) in Combination With Docetaxel in Advanced Gastric Adenocarcinoma Patients With MET Amplification as a Second Line TreatmentCompletedNCT02447406Phase 1/2
- Study of AZD6094 (Volitinib) in Combination With Docetaxel, in Advanced Gastric Adenocarcinoma Patients With MET Overexpression as a Second-line TreatmentCompletedNCT02447380Phase 2
- A Phase I Study of Safety and Pharmacokinetics of Volitinib in Combination With Gefitinib in EGFR(+) NSCLCCompletedNCT02374645Phase 1
- A Study of Safety and Pharmacokinetics of Volitinib With Docetaxel in Patients With Advanced Gastric CancerCompletedNCT02252913Phase 1
- SAFIR02_Lung - Efficacy of Targeted Drugs Guided by Genomic Profiles in Metastatic NSCLC PatientsCompletedNCT02117167Phase 2
- A Food Effect Phase I Study of the Volitinib in Healthy SubjectsCompletedNCT02017236Phase 1
- Phase I Study of the Volitinib (HMPL-504) in Patients With Advanced Solid TumorsCompletedNCT01985555Phase 1
- Phase I Study of the Volitinib (HMPL-504) in Patients With Advanced Solid TumorsCompletedNCT01773018Phase 1